The stock of Cerecor Inc (NASDAQ:CERC) is a huge mover today! About 1.21M shares traded hands or 704.87% up from the average. Cerecor Inc (NASDAQ:CERC) has risen 31.11% since April 27, 2016 and is uptrending. It has outperformed by 25.88% the S&P500.
The move comes after 7 months negative chart setup for the $17.11M company. It was reported on Nov, 30 by Barchart.com. We have $1.90 PT which if reached, will make NASDAQ:CERC worth $855,500 less.
Analysts await Cerecor Inc (NASDAQ:CERC) to report earnings on March, 22. They expect $-0.58 EPS, down 9.43% or $0.05 from last year’s $-0.53 per share. After $-0.70 actual EPS reported by Cerecor Inc for the previous quarter, Wall Street now forecasts -17.14% EPS growth.
According to Zacks Investment Research, “Cerecor, Inc. is a biopharmaceutical company which focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company’s portfolio of clinical and preclinical candidates consists of CERC-301, CERC-501 and CERC-406. CERC-301; adjunctive antidepressant for the treatment of patients with major depressive disorder; CERC-501, for co-occurring psychiatric and substance use disorders and CERC-406, for the treatment of residual cognitive impairment symptoms. Cerecor, Inc. is headquartered in Baltimore, Maryland.”
More important recent Cerecor Inc (NASDAQ:CERC) news were published by: Marketwatch.com which released: “Cerecor Inc.” on November 22, 2013, also Businesswire.com published article titled: “Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in …”, Businesswire.com published: “Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA …” on December 21, 2015. More interesting news about Cerecor Inc (NASDAQ:CERC) was released by: Reuters.com and their article: “BRIEF-Cerecor Inc – files for $75 million mixed shelf offering” with publication date: November 08, 2016.
CERC Company Profile
Cerecor, Inc., incorporated on January 31, 2011, is a clinical stage biopharmaceutical company. The Firm is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Firm has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Firm owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme that is critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. The Company’s COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT found within the central nervous system. The Company’s COMTi platform includes compounds with varying degrees of selectivity of peripheral versus brain COMT inhibition, including some that work on both peripheral and brain COMT, and some that work primarily on brain COMT.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.